TY - JOUR
T1 - Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
JO - Drug Design, Development and Therapy
UR - http://eprints.whiterose.ac.uk/107903/
PY - 2015/09/03
AU - Wolin E
AU - Jarzab B
AU - Eriksson B
AU - Walter T
AU - Toumpanakis C
AU - Morse MA
AU - Tomassetti P
AU - Weber MM
AU - Fogelman D
AU - Ramage J
AU - Poon D et al
ED -
DO - DOI: 10.2147/DDDT.S84177
PB - Dove Medical Press
VL - 9
SP - 5075
EP - 5075
Y2 - 2025/07/08
ER -